{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG000","spread":"NA","value":"5.509"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG001","spread":"NA","value":"10.369"},{"groupId":"OG002","spread":"18.5","value":"16.004"},{"groupId":"OG003","spread":"29.7","value":"36.526"},{"groupId":"OG004","spread":"11.6","value":"58.410"},{"groupId":"OG005","spread":"29.7","value":"62.563"},{"groupId":"OG006","spread":"32.5","value":"71.196"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG000","spread":"NA","value":"5.306"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG001","spread":"NA","value":"9.157"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG002","spread":"NA","value":"15.047"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG003","spread":"NA","value":"36.333"},{"groupId":"OG004","spread":"21.4","value":"51.541"},{"groupId":"OG005","spread":"11.9","value":"57.759"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"description":"The AUC0-last of conjugated enapotamab vedotin for 1Q3W dose-escalation part is reported. Sample scheduling of the 3Q4W dosing regimen did not allow calculation of the specific outcome measure.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.3 mg/kg 1Q3W until the end of treatment.","id":"OG000","title":"Dose-escalation Part: Enapotamab Vedotin 0.3 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 1Q3W until the end of treatment.","id":"OG001","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 1Q3W until the end of treatment.","id":"OG002","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.5 mg/kg 1Q3W until the end of treatment.","id":"OG003","title":"Dose-escalation Part: Enapotamab Vedotin 1.5 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.0 mg/kg 1Q3W until the end of treatment.","id":"OG004","title":"Dose-escalation Part: Enapotamab Vedotin 2.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG005","title":"Dose-escalation Part: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.4 mg/kg 1Q3W until the end of treatment.","id":"OG006","title":"Dose-escalation Part: Enapotamab Vedotin 2.4 mg/kg 1Q3W"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants who were exposed to at least 1 dose of enapotamab vedotin and who had at least 1 postdose PK measurement. 'Number analyzed' denotes the number of participants evaluated for the specified time point.","reportingStatus":"POSTED","timeFrame":"Predose, EOI, and 2 and 5 hours after EOI on Day 1 of Cycles 1 and 3","title":"Area Under the Plasma Concentration-time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of Conjugated Enapotamab Vedotin for 1Q3W Dose-escalation Part","type":"SECONDARY","unitOfMeasure":"day*ug/mL"}